Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4

Colorectal Cancer Clinical Trial

Official title:

Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin Toxicity and Disease Response to Treatment With Erbitux Requirements

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01726309
• Other study ID #: ICORG 08-40
• Status: Terminated
• Start date: May 2011
• Est. completion date: May 11, 2021

Study information

• Verified date: April 2023
• Source: Cancer Trials Ireland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Primary Objective:

Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.

Secondary Objectives:

Correlation of SNP profile with indicators of tumour response parameters, such as radiological response, duration of response, time to progression (TTP), overall survival (OS) time, incidence of non-dermatological adverse events.

Description:

Baseline assessment:

• Contact Lenses

• Medical History

• Previous chemotherapy

• Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)

• Symptom Assessment (Pre-existing skin and/or eye conditions, CEA measurement (CRC only), Disease status (TNM Staging))

• Planned chemotherapy regimen

• Radiotherapy

Blood Sample: A 2ml blood sample should be collected in ethylenediamine-tetraacetic acid (EDTA) containing Vacutainer at any time before or after starting treatment. DNA will be extracted from the samples and the 11 SNPs in the region of the EGFR gene encoding domain III will be characterized.

Follow-up Assessment: with every second cycle of Cetuximab- or Panitumumab-containing regimen (CRC: every 2. Week; NSCLC: every 3-4 weeks):

• Visit Number and Date

• Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)

• Symptom Assessment (CEA measurement (CRC only), Disease status (TMN Staging), Skin Toxicity (CTCAE) grading)

• Current chemotherapy regimen

• Radiotherapy

• CEA measurement only for CRC (every second cycle/every 4 weeks)

Long-term follow-up (up to 5 years):

• CT restaging (TNM Staging) should be done 3 monthly for as long as the subject is receiving Cetuximab- or Panitumumab- containing regimen or if there is suspicion of disease progression.

• OS

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 161
• Est. completion date: May 11, 2021
• Est. primary completion date: May 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Stage IV (AJCC 7th Edition TMN Staging, Appendix C), histologically confirmed CRC with wild-type KRAS and not a candidate for metastasectomy.

2. Stage IV (AJCC 7th Edition, TMN Staging, Appendix C) NSCLC expressing EGFR (IHC tested)

3. Patients, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab).

4. Karnofsky performance status (Appendix B) score =60.

5. Acceptable laboratory values:

• Haemoglobin = 9 g/dL.

• Neutrophil count = 1.0 x 10^9/L.

• Platelet count =100 x 10^9/L.

• Serum creatinine =1.5 times the upper limit of normal.

• Bilirubin =1.5 times the upper limit of normal.

• Aspartate aminotransferase and alanine aminotransferase =5 times the upper limit of normal.

Exclusion Criteria:

1. Aged < 18 years

2. Prior exposure to Cetuximab or Panitumumab

3. The CRC does not carry wild-type KRAS.

4. The NSCLC stains negative for EGFR protein expression

5. Second cancer diagnosis (apart from non-melanoma skin cancer)

6. Known hypersensitivity to Cetuximab or Panitumumab, or murine protein.

7. Known history of coronary artery disease, arrhythmias, or congestive heart failure (If the treating physician feels that a patient's coronary artery disease / arrhythmia / congestive heart failure does not place him/her at risk from treatment with an anti-EGFR antibody, the person can be included. This is a clinical decision, which has to be made by the treating physician).

8. Known to be pregnant (pregnancy test is not mandatory) or breast-feeding.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Colorectal Cancer
• Colorectal Neoplasms
• Non-Small Cell Lung Cancer

Locations

Country	Name	City	State
Ireland	Bon Secours Hospital	Cork
Ireland	Cork University Hospital	Cork
Ireland	Beaumont Hospital	Dublin
Ireland	Mater Misericordiae University Hospital	Dublin
Ireland	St Vincent's University Hospital	Dublin
Ireland	The Adelaide & Meath Hosptal, Dublin Incorporating The National Children's Hospital	Dublin
Ireland	Galway University Hospital	Galway
Ireland	Letterkenny General Hospital	Letterkenny	Donegal
Ireland	Our Lady of Lourdes Hospital, Drogheda	Louth
Ireland	Waterford Regional Hospital	Waterford

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Trials Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.	Using Common Terminology Criteria for Adverse Events (CTCAE) version 4	Throughout treatment with up to 5 years in follow up
Secondary	Correlation between the SNP profile(s) and disease response	Time to progression TTP and OS over 5 years	Throughout treatment with up to 5 years in follow up